Anabolic effects of growth hormone treatment in young children with cystic fibrosis
- PMID: 9791837
- DOI: 10.1080/07315724.1998.10718788
Anabolic effects of growth hormone treatment in young children with cystic fibrosis
Abstract
Background: Malnutrition is commonly found in children with Cystic Fibrosis (CF) and is characterized by poor weight gain and linear growth. Almost one-third of children with CF are below 5th percentile for weight and height. Intensive nutritional supplementation may not result in sustained improvement in weight gain and linear growth.
Objective: To evaluate the anabolic effects of GH, Humatrope (Eli Lilly, 0.05 mg/kg/day) was administered to five children with CF (3 males/2 females) for an average period of 2 years.
Methods: All patients were maintained on caloric intake of 1.3-2.0 times the recommended daily allowance. Patients underwent standard growth hormone (GH) stimulation studies and measurement of IGF-1 and IGFBP-3.
Results: The mean +/- SE for age and skeletal age were 3.2 +/- 0.85 years and 2.0 +/- 0.45 years, respectively. Growth was assessed by determining both weight and height, which were normalized for age and sex by calculating Z scores using HANES I reference data. Differences in Z scores between clinic visits (delta Z) were calculated for both weight and height to determine changes in growth velocity. The mean Z scores for weight and height were markedly attenuated in CF children as compared with healthy children (-1.95 +/- 0.23 and -2.8 +/- 0.27, respectively). The mean +/- SE for maximum stimulated GH value, IGF-1 and IGFBP-3 were 9.2 +/- 1.2 ng/dl, 67 +/- 6 ng/ml, and 1.7 +/- 0.22 mg/L, respectively. GH treatment improved weight and height Z scores (-0.11 +/- 0.05 and -0.94 +/- 0.18, p < 0.01) significantly. The delta Z scores for weight and height were significantly increased during first and second year of GH treatment (p < 0.02). Also, the average values of IGF-1 and IGFBP-3 were significantly increased as compared to pretreatment values (186 +/- 37 ng/ml and 3.0 +/- 0.22 mg/L, p < 0.01).
Conclusions: GH treatment significantly improves weight and linear growth in young patients with CF. These data suggest that anabolic effects of GH may be beneficial for treatment of malnutrition in children with CF.
Comment in
-
Growth hormone (GH) treatment in non-GH deficient chronic disease.J Am Coll Nutr. 1998 Oct;17(5):405-6. doi: 10.1080/07315724.1998.10718785. J Am Coll Nutr. 1998. PMID: 9791834 No abstract available.
Similar articles
-
Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience.J Pediatr. 1997 Jul;131(1 Pt 2):S65-9. doi: 10.1016/s0022-3476(97)70015-5. J Pediatr. 1997. PMID: 9255232
-
Insulin-like growth factor-I levels predict weight, height and protein catabolism in children and adolescents with cystic fibrosis.J Pediatr Endocrinol Metab. 2009 May;22(5):417-24. doi: 10.1515/jpem.2009.22.5.417. J Pediatr Endocrinol Metab. 2009. PMID: 19618660
-
IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.Horm Res. 2005;64(2):68-76. doi: 10.1159/000087692. Epub 2005 Aug 19. Horm Res. 2005. PMID: 16113581
-
GH improves growth and clinical status in children with cystic fibrosis -- a review of published studies.Eur J Endocrinol. 2004 Aug;151 Suppl 1:S81-5. doi: 10.1530/eje.0.151s081. Eur J Endocrinol. 2004. PMID: 15339250 Review.
-
Somatic growth in cystic fibrosis.Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):38-46. doi: 10.1097/MED.0000000000000522. Curr Opin Endocrinol Diabetes Obes. 2020. PMID: 31815786 Review.
Cited by
-
Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin).Biologics. 2008 Dec;2(4):655-61. doi: 10.2147/btt.s2252. Biologics. 2008. PMID: 19707446 Free PMC article.
-
Appetite stimulants for people with cystic fibrosis.Cochrane Database Syst Rev. 2022 Sep 23;9(9):CD008190. doi: 10.1002/14651858.CD008190.pub3. Cochrane Database Syst Rev. 2022. PMID: 36149378 Free PMC article.
-
A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis.Pediatr Pulmonol. 2012 Mar;47(3):252-63. doi: 10.1002/ppul.21546. Epub 2011 Sep 8. Pediatr Pulmonol. 2012. PMID: 21905270 Free PMC article. Clinical Trial.
-
Recombinant growth hormone therapy for cystic fibrosis in children and young adults.Cochrane Database Syst Rev. 2013 Jun 5;6(6):CD008901. doi: 10.1002/14651858.CD008901.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2015 May 20;(5):CD008901. doi: 10.1002/14651858.CD008901.pub3. PMID: 23737090 Free PMC article. Updated.
-
Management of osteoporosis in adults with cystic fibrosis.Drugs. 2004;64(2):133-47. doi: 10.2165/00003495-200464020-00002. Drugs. 2004. PMID: 14717616 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous